Share on StockTwits

Analysts at Jefferies Group hoisted their price objective on shares of Amgen (NASDAQ:AMGN) from $133.00 to $138.00 in a research report issued to clients and investors on Wednesday, Analyst Ratings.Net reports. Jefferies Group’s price objective indicates a potential upside of 14.33% from the stock’s previous close.

Several other analysts have also recently commented on the stock. Analysts at Ned Davis Research upgraded shares of Amgen from a “neutral” rating to a “buy” rating in a research note to investors on Monday. Separately, analysts at TheStreet reiterated a “buy” rating on shares of Amgen in a research note to investors on Tuesday, January 14th. Finally, analysts at Nomura initiated coverage on shares of Amgen in a research note to investors on Wednesday, January 8th. They set a “neutral” rating and a $131.00 price target on the stock. Nine research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $123.39.

Amgen (NASDAQ:AMGN) opened at 120.70 on Wednesday. Amgen has a 52 week low of $82.92 and a 52 week high of $124.46. The stock has a 50-day moving average of $116. and a 200-day moving average of $112.8. The company has a market cap of $91.023 billion and a price-to-earnings ratio of 18.80.

Amgen (NASDAQ:AMGN) last announced its earnings results on Tuesday, January 28th. The company reported $1.82 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.69 by $0.13. The company had revenue of $5.01 billion for the quarter, compared to the consensus estimate of $4.81 billion. During the same quarter in the previous year, the company posted $1.40 earnings per share. The company’s revenue for the quarter was up 13.1% on a year-over-year basis. On average, analysts predict that Amgen will post $7.46 earnings per share for the current fiscal year.

Amgen Inc is a global biotechnology pioneer that discovers, develops, manufactures and delivers human therapeutics.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.